ArticleTrends in endocrinology and metabolism: TEM2014
In search of a surrogate: engineering human beta cell lines for therapy.
Article in Trends in endocrinology and metabolism: TEM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development of scaffold-free vascularized pancreatic beta-islets in vitro models by the anchoring of cell lines to a bioligand-functionalized gelatine substrate.Journal of materials science. Materials in medicine · 2022Article
- Immunogenicity of human embryonic stem cell-derived beta cells.Diabetologia · 2017Article
- A human beta cell line with drug inducible excision of immortalizing transgenes.Molecular metabolism · 2015Article
- Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines.American journal of physiology. Regulatory, integrative and comparative physiology · 2015Article
- Optogenetic control of insulin secretion by pancreatic β-cells in vitro and in vivo.Gene therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Replacement of insulin-producing cells is a promising therapy for the restoration of the beta cell mass that is destroyed in patients with type 1 diabetes (T1D). However, the use of large amounts of islets per transplant, coupled with the scarcity of donor tissue, diminishes its feasibility. Here we briefly discuss current progress in developing ideal functional beta cells as well as the rationale for developing renewable sources of insulin-producing cells that can be transplanted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.